Fasenra

Fasenra

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Benralizumab
Indications/Uses
Add-on maintenance treatment in adult patients w/ severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
Dosage/Direction for Use
SC Adult 30 mg inj every 4 wk for the 1st 3 doses then every 8 wk thereafter.
Contraindications
Special Precautions
Discontinue use in the event of a hypersensitivity reaction. Not for treatment of acute asthma exacerbations. Instruct patients to seek medical advice if asthma remains uncontrolled or worsens after initiation of treatment. Not recommended to abruptly discontinue corticosteroids after Fasenra initiation. Patients w/ known helminth infections; treat pre-existing helminth infections before initiating therapy. Discontinue use if patients become infected while receiving treatment & do not respond to antihelminthics. Avoid use during pregnancy; consider use only if the expected benefit to the mother is greater than any possible risk to the fetus. Lactation. Childn <12 yr.
Adverse Reactions
Headache; pharyngitis; pyrexia, inj site reactions; hypersensitivity reactions.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03DX10 - benralizumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Fasenra soln for inj 30 mg/mL
Packing/Price
(autoinjector) 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in